FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in …
Mar 26, 2024 · WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and …
Winrevair, PAH treatment for adults, likely available soon in US
Apr 10, 2024 · Winrevair (sotatercept-csrk), the under-the-skin injectable treatment recently approved in the U.S. for adults with pulmonary arterial hypertension (PAH), is expected to be …
Winrevair: FDA approves new drug that may help stop PAH | CNN
Mar 26, 2024 · Winrevair was approved by the FDA on Tuesday to help treat pulmonary arterial hypertension. Winrevair is a biologic drug designed to grab onto and trap proteins called …
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR …
Nov 25, 2024 · WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at …
Winrevair 'overwhelming' at treating advanced PAH in Phase 3 trial
Nov 27, 2024 · Winrevair (sotatercept-csrk) significantly reduced the risk of all-cause death, a lung transplant, or hospitalization among adults with pulmonary arterial hypertension (PAH) at …
FDA approves sotatercept, now Winrevair, to treat PAH in adults
Mar 27, 2024 · The U.S. Food and Drug Administration (FDA) has approved the under-the-skin injection therapy sotatercept-csrk — to be marketed under the brand name Winrevair — to …
Merck's Therapy for Rare Lung Condition Shown to Help Reduce …
Nov 25, 2024 · (Reuters) - Merck said on Monday its drug, Winrevair, helped significantly reduce the risk of death in patients with a rare condition which causes high blood pressure in the …
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR …
Nov 25, 2024 · WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at …
Merck Drug for Heart and Lung Disorder Wins a First-in ... - MedCity News
Mar 26, 2024 · Merck drug Winrevair is the first in a new class of pulmonary arterial hypertension therapies that address a key signaling pathway behind the disease. The drug comes from …
FDA approves Winrevair for pulmonary arterial hypertension in …
Mar 29, 2024 · The U.S. Food and Drug Administration has approved Winrevair (sotatercept-csrk) as an injectable treatment for pulmonary arterial hypertension (PAH) in adults.
- Some results have been removed